Mosaico HIV vaccine trial fails
[ad_1]
Trials of Mosaico’s experimental HIV vaccine, which have been ongoing since 2019, have been ineffective. About it informs vaccine manufacturer Janssen, part of the Johnson & Johnson group.
Control group studies have shown that the vaccine is about as effective as a placebo.
The effectiveness of Mosaico was tested on 3900 men (MSM) and transgender people from Europe and the USA. During the year, each study participant received four doses of the vaccine or placebo.
According to an independent Data and Safety Monitoring Committee, the researchers found no safety issues with the drug, but the incidence of HIV infection was similar between those who received the vaccine and placebo.
As the developer of the drug emphasized, all participants received all available means to prevent HIV, including pre-exposure prophylaxis.
[ad_2]
Source link
